MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles(Queen Mary University of London), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Siew-leng Melinda Teng(Genesys (United States)), Yohann Loriot(Institut Gustave Roussy), Daniel S. Chen(Synthetic Genomics (United States)), Joseph P. Eder(Yale Cancer Center), Daniel P. Petrylak(Yale University), Gregg Fine(Genesys (United States)), Howard A. Burris(Deaconess Hospital), Joaquim Bellmunt(Dana-Farber Cancer Institute), Xiaodong Shen(Fudan University), Fadi S. Braiteh(Comprehensive Cancer Centers of Nevada), Cristina Cruz(Vall d'Hebron Institut de Recerca), Priti S. Hegde(Foundation Medicine (United States)), Zachary Boyd(Genesys (United States))
Cited by 2,421
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k